Acumen Pharmaceuticals In... (ABOS)
Acumen Pharmaceuticals Statistics
Share Statistics
Acumen Pharmaceuticals has 60.57M shares outstanding. The number of shares has increased by 0% in one year.
Shares Outstanding | 60.57M |
Shares Change (YoY) | 0% |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | 70.73% |
Shares Floating | 44.28M |
Failed to Deliver (FTD) Shares | 2.44K |
FTD / Avg. Volume | 0.94% |
Short Selling Information
The latest short interest is 1.83M, so 3.04% of the outstanding shares have been sold short.
Short Interest | 1.83M |
Short % of Shares Out | 3.04% |
Short % of Float | 4.17% |
Short Ratio (days to cover) | 4.48 |
Valuation Ratios
The PE ratio is -1.01 and the forward PE ratio is -1.05. Acumen Pharmaceuticals's PEG ratio is -0.02.
PE Ratio | -1.01 |
Forward PE | -1.05 |
PS Ratio | 0 |
Forward PS | 1.2 |
PB Ratio | 0.57 |
P/FCF Ratio | -1.2 |
PEG Ratio | -0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Acumen Pharmaceuticals.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.46, with a Debt / Equity ratio of 0.16.
Current Ratio | 6.46 |
Quick Ratio | 6.46 |
Debt / Equity | 0.16 |
Debt / EBITDA | -0.29 |
Debt / FCF | -0.33 |
Interest Coverage | -28.03 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $-1.68M |
Employee Count | 61 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -72.63% in the last 52 weeks. The beta is 0.02, so Acumen Pharmaceuticals's price volatility has been higher than the market average.
Beta | 0.02 |
52-Week Price Change | -72.63% |
50-Day Moving Average | 1.35 |
200-Day Moving Average | 2.19 |
Relative Strength Index (RSI) | 34.7 |
Average Volume (20 Days) | 257.91K |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -114.02M |
Net Income | -102.33M |
EBITDA | -98.08M |
EBIT | -98.26M |
Earnings Per Share (EPS) | -1.71 |
Balance Sheet
The company has 35.63M in cash and 28.73M in debt, giving a net cash position of 6.89M.
Cash & Cash Equivalents | 35.63M |
Total Debt | 28.73M |
Net Cash | 6.89M |
Retained Earnings | -325.13M |
Total Assets | 238.99M |
Working Capital | 150.7M |
Cash Flow
In the last 12 months, operating cash flow was -86.22M and capital expenditures -16K, giving a free cash flow of -86.23M.
Operating Cash Flow | -86.22M |
Capital Expenditures | -16K |
Free Cash Flow | -86.23M |
FCF Per Share | -1.44 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
ABOS does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for ABOS is $7, which is 554.2% higher than the current price. The consensus rating is "Buy".
Price Target | $7 |
Price Target Difference | 554.2% |
Analyst Consensus | Buy |
Analyst Count | 3 |
Scores
Altman Z-Score | -1.83 |
Piotroski F-Score | 2 |